stock price decline

Plug Power faces class action lawsuit alleging false statements about DOE loans and hydrogen facilities. Investors have until April 3, 2026 to apply as lead plaintiffs.

Ramaco Resources faces class action lawsuit over alleged false Brook Mine operational claims, with lead plaintiff deadline set for March 31, 2026.

Pomerantz LLP investigates Disc Medicine ($IRON) for potential securities fraud after FDA rejected bitopertin drug application, triggering consecutive stock declines totaling over 28%.

Pomerantz LLP investigates Banco Santander for potential securities fraud over undisclosed UK lender collapse, with stock falling 7.57% over two trading sessions.

Valneva stock plummets 37% after Phase 3 Lyme vaccine candidate fails trial; law firm investigates potential securities fraud claims.

BlackRock faces securities fraud investigation after implementing 5% quarterly redemption caps on HPS Corporate Lending Fund, triggering 7.69% stock decline.

Pomerantz Law Firm investigates potential securities fraud at Babcock & Wilcox following allegations linking a major power contract to its largest shareholder.

Microvast ($MVST) plunged 34% after reporting $96.5M revenue (29% below consensus) and 1% gross margins, triggering securities fraud investigation by Pomerantz LLP.

Pomerantz LLP investigates Freshpet for potential securities fraud tied to unsupported 'human grade' pet food claims, triggering sharp stock decline.

Pomerantz Law Firm investigates $CFLT over undisclosed AI customer spending reduction that caused stock to crash 32.86% on July 31, 2025.

$LAKE faces class action suit alleging executives misrepresented acquisition integration and hid operational problems, leading to 39% stock crash.

Pomerantz Law Firm files class action against Enphase Energy over alleged misstatements regarding inventory management and federal solar tax credit impacts. Stock fell 15.15% after weak Q3 guidance.

Navan investors face April 2026 deadline to join class action over allegedly misleading IPO disclosures. Stock has fallen 63% after undisclosed 39% expense increase announcement.

Law firm investigates Stellantis for potential securities violations after €22.2 billion charge announcement triggers 23.7% stock plunge to $7.28.

Aquestive Therapeutics faces securities fraud lawsuit after FDA rejected Anaphylm drug, contradicting management's prior "on track" statements; $AQST stock fell 37%.

$DRVN plunged nearly 40% after disclosing accounting errors and control weaknesses requiring multi-year restatement. Securities fraud lawsuit filed with May 8 deadline.

Alight Inc. faces securities fraud lawsuit after missing guidance twice, with stock falling 18-38%. Shareholders can claim losses through May 2026.

Portnoy Law Firm investigates Upstart Holdings for securities fraud following November 5 disclosure that its Model 22 underwriting system underperformed, causing sharp stock decline and investor losses.

Soleno Therapeutics faces class action lawsuit over alleged failure to disclose safety issues with drug DCCR, following 12-27% stock declines from August-September 2025 revelations.

Law firm investigates $TBRG for potential securities violations after revealing out-of-period accounting errors spanning 2023-2025. Stock fell 10.5%.